Merck's Bridion faces generic threat from drugmaker Hikma [Yahoo! Finance]
HIKMA PHARMS PLC S/ADR (HKMPY)
NASDAQ:AMEX Investor Relations:
hikma.com/en/investors.html
Company Research
Source: Yahoo! Finance
a generic version of its Bridion injection, the drugmaker said in filing on Monday. Merck said, on Feb. 5, it received the letter under the Hatch-Waxman Act, through which a company can seek FDA approval to market a copycat before the expiration of patents related to the brand-name drug. Merck said in the filing that it is currently considering its options. Both Merck and Hikma did not immediately respond to Reuters requests for comment. Bridion, chemically known as sugammadex, is approved to reverse the effects of muscle relaxants used in surgery. The injection has a patent protection through at least Jan. 2026. (Reporting by Sriparna Roy in Bengaluru; Editing by Shailesh Kuber)
Show less
Read more
Impact Snapshot
Event Time:
HKMPY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HKMPY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HKMPY alerts
High impacting HIKMA PHARMS PLC S/ADR news events
Weekly update
A roundup of the hottest topics
HKMPY
News
- With 52% institutional ownership, Hikma Pharmaceuticals PLC (LON:HIK) is a favorite amongst the big guns [Yahoo! Finance]Yahoo! Finance
- Rakuten Medical Closes $119 Million Series E Financing to Further Develop its Alluminox™ Platform [Yahoo! Finance]Yahoo! Finance
- Hyloris Announces Launch of Maxigesic® IV in the U.S. and approval In Canada [Yahoo! Finance]Yahoo! Finance
- Merck's Bridion faces generic threat from drugmaker Hikma [Reuters]Reuters
- Hikma hosts White House Drug Policy Director Dr. Rahul Gupta at its Columbus, Ohio manufacturing facilityPR Newswire